Mevrometostat

Small molecule

Phase 3underway

Evidence outlook · registrational

Metastatic Castration-Resistant Prostate Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-09-30.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Metastatic Castration-Resistant Prostate Cancer
NCT06629779 · Pfizer
2024-10-22 – 2028-11-30 · Metastatic Castration-Resistant Prostate Cancer
What this study did
Other / comorbidity
NCT07028853 · Pfizer
2025-09-28 – 2034-12-08 · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
What this study did
NCT06551324 · Pfizer
2024-10-21 – 2028-10-29 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)
What this study did
Phase 2 (1)
Other / comorbidity
NCT07592910 · Prostate Cancer Clinical Trials Consortium
2026-08 – 2029-08 · Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma)
What this study did
Phase 1 (4)
Metastatic Castration-Resistant Prostate Cancer
NCT03460977 · Pfizer
2018-04-17 – 2029-07-07 · Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
What this study did
Other / comorbidity
NCT06661694 · Pfizer
2025-04-28 – 2025-09-09 · Healthy
What this study did
NCT06392230 · Pfizer
2024-08-30 – 2024-11-11 · Healthy Participants
What this study did
NCT05767905 · Pfizer
2023-03-17 – 2023-06-20 · Healthy
What this study did

Competitive landscape

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mevrometostat: this drugPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
FluzoparibPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
OpevesostatPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Zadavotide GuraxetanPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
LuxdegalutamidePhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
AKY-2519Phase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Mevrometostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 3Metastatic Castrate Resistant Prostate Cancer (mCRPC)Active not recruiting
Est. primary completion 2027-02-28 · NCT06551324 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT06629779 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 1Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2028-04-20 · NCT03460977 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the ProstateRecruiting
Est. primary completion 2028-09-12 · NCT07028853 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 2Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma)Not yet recruiting
Est. primary completion 2029-05 · NCT07592910 · CT.gov ↗
What to watch

See the full readout calendar ↗